by Brad Dunn | Jan 15, 2021
The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Xalkori (crizotinib) for patients between the ages of 1 and 21 years of age with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The latest development...
by Brad Dunn | Jan 15, 2021
Elizabeth Berry-Kravis, MD, PhD, co-director of the Molecular Diagnostics Section of the Genetic Laboratory at Rush Medical College in Chicago, provides an overview of Niemann-Pick Type C (NPC). NPC is a disabling neurogenetic disorder that has been diagnosed...
by Brad Dunn | Jan 14, 2021
Ally Roets and her son Sam — who was diagnosed with facioscapulohumeral muscular dystrophy (FSHD) when he was age 6 — describe the early symptoms that eventually led them to a diagnosis. FSHD is a rare disabling disease characterized by progressive skeletal...
by Brad Dunn | Jan 14, 2021
Dr. Anna Sureda, Head of the Onco-Hematology Service at Blood Cell Barcelona, gives an overview of Hodgkin lymphoma (HL). HL is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and...
